Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Lechner M, Liu J, Masterson L, et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022 May;19(5):306–327.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15;141(4):664–670. doi: 10.1002/ijc.30716
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467–475.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340–1348. doi: 10.1056/NEJMoa1917338
   PubMed Web of Science ®Google Scholar
• Schernberg A, Sagaon-Teyssier L, Schwarzinger M. Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France. Clinicoecon Outcomes Res. 2019;11:441–451. doi: 10.2147/CEOR.S198312
   PubMed Web of Science ®Google Scholar
• Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020 Nov 26;6(1):92. doi: 10.1038/s41572-020-00224-3
   PubMedGoogle Scholar
• Kriegs M, Clauditz TS, Hoffer K, et al. Analyzing expression and phosphorylation of the EGF receptor in HNSCC. Sci Rep. 2019 Sep 19;9(1):13564. doi: 10.1038/s41598-019-49885-5
   PubMedGoogle Scholar
• Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129–1136. doi: 10.1016/0092-8674(90)90409-8
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley PM, Münger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989 Feb 17;243(4893):934–937. doi: 10.1126/science.2537532
   PubMed Web of Science ®Google Scholar
• Stavrou S, Ross SR. APOBEC3 Proteins in Viral Immunity. J Immunol. 2015 Nov 15;195(10):4565–4570. doi: 10.4049/jimmunol.1501504
   PubMed Web of Science ®Google Scholar
• Henderson S, Chakravarthy A, Su X, et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 2014 Jun 26;7(6):1833–1841. doi: 10.1016/j.celrep.2014.05.012
   PubMed Web of Science ®Google Scholar
• Gillison ML, Akagi K, Xiao W, et al. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res. 2019 Jan;29(1):1–17.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674. doi: 10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Welters MJP, Ma W, Santegoets S, et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in hpv16-driven oropharyngeal cancer. Clin Cancer Res. 2018 Feb 1;24(3):634–647. doi: 10.1158/1078-0432.CCR-17-2140
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008 Jul 15;112(2):362–373. doi: 10.1182/blood-2007-11-120998
   PubMed Web of Science ®Google Scholar
• Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009 Apr;21(2):200–208. doi: 10.1016/j.coi.2009.02.004
   PubMed Web of Science ®Google Scholar
• Wusiman D, Guo L, Huang Z, et al. The clinicopathological significance of PD-L1 expression assessed by the combined positive score (CPS) in head and neck squamous cell carcinoma. Pathol Res Pract. 2022 Aug;236:153934. doi: 10.1016/j.prp.2022.153934
   PubMed Web of Science ®Google Scholar
• Hong AM, Ferguson P, Dodds T, et al. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncol. 2019 May;92:33–39. doi: 10.1016/j.oraloncology.2019.03.012
   PubMed Web of Science ®Google Scholar
• Carretero M, Cantoni C, Bellón T, et al. The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. Eur J Immunol. 1997 Feb;27(2):563–567.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Athanasiadis I. Chemotherapy of squamous cell carcinoma of head and neck: the future is now. Ann Oncol. 1996 Jan;7(1):15–29. doi: 10.1093/oxfordjournals.annonc.a010467
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang F, Zhang W, et al. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol. 2013 Nov;108(6):387–397.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1;25(16):2171–2177. doi: 10.1200/JCO.2006.06.7447
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116–1127. doi: 10.1056/NEJMoa0802656
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, Hitt R, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol. 2014;32(15_suppl):6021–6021. doi: 10.1200/jco.2014.32.15_suppl.6021
   Google Scholar
• Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011 May;22(5):1078–1087.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Mesia R, Giralt J, et al. p16, HPV, and cetuximab: what is the evidence? Oncology. 2017 Jul;22(7):811–822.
   Google Scholar
• Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013 Jul;14(8):697–710.
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013 Apr 10;31(11):1405–1414. doi: 10.1200/JCO.2012.45.4272
   PubMed Web of Science ®Google Scholar
• de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15;18(8):2336–2343. doi: 10.1158/1078-0432.CCR-11-2825
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of Erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85. doi: 10.1200/JCO.2004.06.075
   PubMed Web of Science ®Google Scholar
• Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015 May;16(5):583–594.
   PubMed Web of Science ®Google Scholar
• Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 2013 Mar;24(3):761–769.
   PubMed Web of Science ®Google Scholar
• Wang Z, Valera JC, Zhao X, et al. mTOR co-targeting strategies for head and neck cancer therapy. Cancer Metastasis Rev. 2017 Sep;36(3):491–502.
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015 Jan 29;517(7536):576–582. doi: 10.1038/nature14129
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019 Jan 12;393(10167):156–167. doi: 10.1016/S0140-6736(18)31999-8
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856–1867. doi: 10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019 Nov 23;394(10212):1915–1928. doi: 10.1016/S0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023 Feb 1;41(4):790–802. doi: 10.1200/JCO.21.02508
   PubMed Web of Science ®Google Scholar
• Tahara M, Greil R, Rischin D, et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol. 2022;33:S844. doi: 10.1016/j.annonc.2022.07.783
   Google Scholar
• Carter BW, Bhosale PR, Yang WT. Immunotherapy and the role of imaging. Cancer. 2018 Jul 15;124(14):2906–2922. doi: 10.1002/cncr.31349
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–1356. doi: 10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of checkmate 651. J Clin Oncol. 2023 Apr 20;41(12):2166–2180. doi: 10.1200/JCO.22.00332
   PubMed Web of Science ®Google Scholar
• Psyrri A, Fayette J, Harrington K, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023 Mar;34(3):262–274. doi: 10.1016/j.annonc.2022.12.008
   PubMed Web of Science ®Google Scholar
• Head and neck squamous cell carcinomma (hnscc) market size & share, by drug class (immunotherapy, chemotherapy, Targeted Therapy) - Global Sypply & Demand Analysiis, Growth Forecasts, Statistics Report 2023-2035. 2023 [cited 2023 Dec 13]. Available from: https://www.researchnester.com/reports/head-and-neck-squamous-cell-carcinoma-treatment-and-drugs-market/2839
   Google Scholar
• Burtness B, Rischin D, Greil R, et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in keynote-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022 Jul 20;40(21):2321–2332. doi: 10.1200/JCO.21.02198
   PubMed Web of Science ®Google Scholar
• Trivedi S, Srivastava RM, Concha-Benavente F, et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Res. 2016 Nov 1;22(21):5229–5237. doi: 10.1158/1078-0432.CCR-15-2971
   PubMed Web of Science ®Google Scholar
• Lee SC, Srivastava RM, López-Albaitero A, et al. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011 Aug;50(2–3):248–254.
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013 Apr 1;19(7):1858–1872. doi: 10.1158/1078-0432.CCR-12-2426
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006 Jun 15;12(12):3657–3660. doi: 10.1158/1078-0432.CCR-06-0818
   PubMed Web of Science ®Google Scholar
• Knowles LM, Stabile LP, Egloff AM, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 2009 Jun 1;15(11):3740–3750. doi: 10.1158/1078-0432.CCR-08-3252
   PubMed Web of Science ®Google Scholar
• Bauman JE, Ohr J, Gooding WE, et al. Phase I study of ficlatuzumab and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer. Cancers (Basel). 2020 Jun 11;12(6):1537. doi: 10.3390/cancers12061537
   PubMed Web of Science ®Google Scholar
• Wu Z, Song W, Cheng Z, et al. Expression of LGR5 in oral squamous cell carcinoma and its correlation to vasculogenic mimicry. Int J Clin Exp Pathol. 2017;10(11):11267–11275.
   PubMed Web of Science ®Google Scholar
• Saba NF, Vijayvargiya P, Vermorken JB, et al. Targeting angiogenesis in squamous cell carcinoma of the head and neck: opportunities in the immunotherapy era. Cancers (Basel). 2022 Feb 25;14(5):1202. doi: 10.3390/cancers14051202
   PubMed Web of Science ®Google Scholar
• Ziogas AC, Gavalas NG, Tsiatas M, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer. 2012 Feb 15;130(4):857–864. doi: 10.1002/ijc.26094
   PubMed Web of Science ®Google Scholar
• Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012 Oct 22;209(11):2001–2016. doi: 10.1084/jem.20111497
   PubMed Web of Science ®Google Scholar
• Lee JY, Park S, Min WS, et al. Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. Cancer Lett. 2014 Nov 28;354(2):281–289. doi: 10.1016/j.canlet.2014.08.027
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015 Feb 9;212(2):139–148. doi: 10.1084/jem.20140559
   PubMed Web of Science ®Google Scholar
• Licitra L, Tahara M, Harrington K, et al. Pembrolizumab with or without lenvatinib as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 LEAP-010 study. Int J Radiat Oncol Biol Phys. 2024;118(5):e2–e3. doi: 10.1016/j.ijrobp.2024.01.016
   Google Scholar
• Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002 Jan 31;415(6871):536–541. doi: 10.1038/415536a
   PubMed Web of Science ®Google Scholar
• Davar D, Zarour HM. Immunological targets for immunotherapy: inhibitory T cell receptors. Methods Mol Biol. 2020;2055:23–60.
   PubMedGoogle Scholar
• Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb 17;7(1):10501. doi: 10.1038/ncomms10501
   PubMedGoogle Scholar
• Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020 Sep;8(2):e000957. doi: 10.1136/jitc-2020-000957
   PubMed Web of Science ®Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014 Dec 8;26(6):923–937. doi: 10.1016/j.ccell.2014.10.018
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018 Jul;19(7):723–732.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24–34. doi: 10.1056/NEJMoa2109970
   PubMed Web of Science ®Google Scholar
• Choi Y, Shi Y, Haymaker CL, et al. T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2):e000966.
   PubMedGoogle Scholar
• Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010 Jun;22(3):326–332. doi: 10.1016/j.coi.2010.01.001
   PubMed Web of Science ®Google Scholar
• Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):883–892.
   PubMed Web of Science ®Google Scholar
• Forster M, Metcalf R, Sacco J, et al. 922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas. Ann Oncol. 2020 Sep;31:S665. doi: 10.1016/j.annonc.2020.08.1037 Epub 2020 Sep 22.
   PubMedGoogle Scholar
• Gulati S, Crist M, Riaz MK, et al. Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, nonrandomized, phase II clinical trial. Clin Cancer Res. 2023 May 15;29(10):1906–1915. doi: 10.1158/1078-0432.CCR-22-3886
   PubMed Web of Science ®Google Scholar
• Fayette J, Licitra LFL, Harrington KJ, et al. 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI). Ann Oncol. 2023;34:S554–S555.
   PubMed Web of Science ®Google Scholar
• Bauman JE, Saba NF, Roe D, et al. Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, recurrent/metastatic head and neck cancer. J Clin Oncol. 2023;41(22):3851–3862. doi: 10.1200/JCO.22.01994
   PubMedGoogle Scholar
• Cohen EE, Fayette J, Daste A, et al. Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC). Cancer Res. 2023;83(8_Supplement):CT012–CT012. doi: 10.1158/1538-7445.AM2023-CT012
   Web of Science ®Google Scholar
• Adkins D, Ley J, Palka K, et al. 358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial. J Immunother Cancer. 2021;9(Suppl 2):A385–A385. doi: 10.1136/jitc-2021-SITC2021.358
   Google Scholar
• Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022 Jun;23(6):781–792.
   PubMed Web of Science ®Google Scholar
• Roche provides update on phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer. [Internet]. News release; 2023 Aug 23 [cited 2023 Nov 8]. Available from: roche.com/media/releases/med-cor-2023-08-23
   Google Scholar
• Hamid O, Gutierrez M, Mehmi I, et al. A phase 1/2 study of retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) combination therapy in patients (Pts) with advanced solid tumors. J Clin Oncol. 2023;41(16_suppl):2599–2599. doi: 10.1200/JCO.2023.41.16_suppl.2599
   Web of Science ®Google Scholar
• Hansen A, Bauer TM, Moreno V, et al. 1138PD - First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. Ann Oncol. 2018;29:viii 404. doi: 10.1093/annonc/mdy288.011
   Web of Science ®Google Scholar
• Massarelli E, Balmanoukian AS, Vieito M, et al. INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors. J Clin Oncol. 2020;38(15_suppl):6544–6544. doi: 10.1200/JCO.2020.38.15_suppl.6544
   Web of Science ®Google Scholar
• Rischin D, Groenland SL, Lim AML, et al. 1119PD - Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology. 2019;30:v454–v455. doi: 10.1093/annonc/mdz252.011
   Web of Science ®Google Scholar
• GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist. [Internet]. NewsRelease; Apr 14, 2021 [cited Nov 8, 2023]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/2021
   Google Scholar
• Avice MN, Sarfati M, Triebel F, et al. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol. 1999 Mar 1;162(5):2748–2753. doi: 10.4049/jimmunol.162.5.2748
   PubMed Web of Science ®Google Scholar
• Legat A, Maby-El Hajjami H, Baumgaertner P, et al. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell responses in metastatic melanoma patients–report of a phase I/IIa Clinical Trial. Clin Cancer Res. 2016 Mar 15;22(6):1330–1340. doi: 10.1158/1078-0432.CCR-15-1212
   PubMed Web of Science ®Google Scholar
• Felip E, Majem M, Doger B, et al. A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. J Clin Oncol. 2022;40(16_suppl):9003–9003. doi: 10.1200/JCO.2022.40.16_suppl.9003
   Web of Science ®Google Scholar
• Immutep’s efti in combination with pembrolizumab achieves excellent initial overall survival benefit in 1st line non-small cell lung cancer [Internet]. Press releases.; 2023 May 1. [cited 2023 Nov 8]. Available from: https://www.immutep.com/detail/immutep-s-efti-in-combination-with-pembrolizumab-achieves-excellent-initial-overall-survival-benefit-in-1st-line-non-small-cell-lung-cancer.html
   Google Scholar
• BDd S, Felip E, Forster M, et al. Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1. J Clin Oncol. 2023;41(16_suppl):6029–6029. doi: 10.1200/JCO.2023.41.16_suppl.6029
   Web of Science ®Google Scholar
• Stepan LP, Trueblood ES, Hale K, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011 Jul;59(7):701–710.
   PubMed Web of Science ®Google Scholar
• Lombardi P, Filetti M, Falcone R, et al. Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings. Cancers (Basel). 2023 Mar 13;15(6):1744. doi: 10.3390/cancers15061744
   PubMed Web of Science ®Google Scholar
• Guerra E, Trerotola M, Tripaldi R, et al. Trop-2 Induces tumor growth through AKT and determines sensitivity to AKT Inhibitors. Clin Cancer Res. 2016 Aug 15;22(16):4197–4205. doi: 10.1158/1078-0432.CCR-15-1701
   PubMed Web of Science ®Google Scholar
• Zeng P, Chen MB, Zhou LN, et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016 Sep 20;6(1):33658. doi: 10.1038/srep33658
   PubMedGoogle Scholar
• Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008 Feb;21(2):186–191.
   PubMed Web of Science ®Google Scholar
• Wu H, Xu H, Zhang S, et al. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck. 2013 Oct;35(10):1373–1378.
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021 Apr 22;384(16):1529–1541. doi: 10.1056/NEJMoa2028485
   PubMed Web of Science ®Google Scholar
• Michel L, Jimeno A, Sukari A, et al. 859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial. Ann Oncol. 2023;34:S558. doi: 10.1016/j.annonc.2023.09.2005
   Web of Science ®Google Scholar
• Qiu M-Z, Zhang Y, Guo Y, et al. Evaluation of safety of treatment with anti–epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2022;8(7):1042–1046. doi: 10.1001/jamaoncol.2022.0503
   PubMed Web of Science ®Google Scholar
• de Bono JS, Harris JR, Burm SM, et al. Systematic study of tissue factor expression in solid tumors. Cancer Rep (Hoboken). 2023 Feb;6(2):e1699.
   PubMedGoogle Scholar
• Gray E, Hensley K, Allred S, et al. 617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death. J Immunother Cancer. 2020;8(Suppl 3):A371–A372.
   Google Scholar
• Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care. 2018 Feb;24(2):109–112.
   PubMed Web of Science ®Google Scholar
• Borse RH, Ramakrishnan K, Gandhi J, et al. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. J Med Econ. 2022 Jan;25(1):954–965.
   PubMed Web of Science ®Google Scholar
• Derbyshire M. Patent expiry dates for biologicals: 2016 update. GaBI J. 2017;6(1):27–30. doi: 10.5639/gabij.2017.0601.006
   Google Scholar
• Douez E, D’Atri V, Guillarme D, et al. Why is there no biosimilar of Erbitux®? J Pharm Biomed Anal. 2023 Sep 20;234:115544. doi: 10.1016/j.jpba.2023.115544
   PubMed Web of Science ®Google Scholar
• Hannouf MB, Sehgal C, Cao JQ, et al. Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLOS One. 2012;7(6):e38557. doi: 10.1371/journal.pone.0038557
   PubMed Web of Science ®Google Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022 Apr;19(4):254–267. doi: 10.1038/s41571-022-00600-w
   PubMed Web of Science ®Google Scholar
• Gotsman I, Grabie N, Dacosta R, et al. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest. 2007 Oct;117(10):2974–2982.
   PubMed Web of Science ®Google Scholar
• Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol. 2001 Jul;2(7):591–596.
   PubMed Web of Science ®Google Scholar
• Drobni ZD, Alvi RM, Taron J, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020 Dec 15;142(24):2299–2311. doi: 10.1161/CIRCULATIONAHA.120.049981
   PubMed Web of Science ®Google Scholar
• Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024 Mar 7;390(10):875–888. doi: 10.1056/NEJMoa2312117
   PubMed Web of Science ®Google Scholar
• Price KAR, Kaczmar JM, Worden FP, et al. Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2023;41(16_suppl):6012–6012. doi: 10.1200/JCO.2023.41.16_suppl.6012
   Google Scholar
• Sousa LG, Rajapakshe K, Rodriguez Canales J, et al. ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022 Feb;10(2):e004232.
   PubMed Web of Science ®Google Scholar
• Zhang S, Zheng M, Nie D, et al. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis. J Immunother Cancer. 2022 Oct;10(10):e005158.
   PubMed Web of Science ®Google Scholar